Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 104

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 104
---
 globally.

• Established a number of research collaborations regarding the use of our Precise MRD test for breast cancer patients with leading cancer research institutions, including The University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and the National Cancer Center Hospital East in Japan, and a study partnership with Aptitude Health.

• The United States Patent and Trademark Office issued three new patents that further advance our ability to bring our tumor-informed, high-definition, MRD assay, Precise MRD, to market.

• Launched the Universal Plus Panel for Foresight Carrier Screen, which screens up to 272 genes associated with serious inherited conditions.

• Launched early gestational age Prequel Prenatal Screen, which can be performed as early as eight weeks into pregnancy, which is the first and only prenatal cell-free DNA (cfDNA) screen that can be performed at this early gestational age.

• Announced a collaboration with Flatiron Health, a leading health technology company dedicated to point of care solutions in oncology. This collaboration allows physicians to order our MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based EMR platform, OncoEMR.

• We entered into a strategic partnership with jscreen™, a national organization that delivers education and access to genetic testing with a focus on high-risk populations. The collaboration combines our high-quality hereditary cancer and reproductive genetics products, MyRisk with RiskScore and Foresight Carrier Screen, with jscreen’s trusted education and genetic care navigation program.

Based on this performance and the performance set forth above in the "Executive and Director Compensation-Compensation Discussion and Analysis-2024 Fiscal Year Performance" section, we believe that the salaries and annual cash incentive bonuses paid to our President and Chief Executive Officer and our other NEOs are in line with our compensation philosophy and goals. With respect to the short-term incentive awards paid to our NEOs for the 2024 fiscal year, we paid between 104.7 percent and 125.6 percent, respectively, of the target awards, based on the level of accomplishment of the pre-determined incentive goals.

In accordance with the rules of the SEC, the following resolution, commonly known as a “Say-on-Pay” vote, is being submitted for a stockholder vote at the Annual Meeting:

71

“RESOLVED, that the compensation paid to the named executive officers of Myriad Genetics, Inc., as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission,